Ludovica Ganino
Catanzaro, 88100, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
OPA1 as a Cancer Target: Molecular Mechanisms, Structural Insights, and Strategies for Drug Development.
Journal: Antioxidants (Basel, Switzerland)
Published: December 22, 2025
Correction: Targeting the MARCH5-MFN2 axis to enhance mitochondrial fusion and sensitize multiple myeloma cells to venetoclax.
Journal: Journal of translational medicine
Published: November 11, 2025
Targeting the MARCH5-MFN2 axis to enhance mitochondrial fusion and sensitize multiple myeloma cells to venetoclax.
Journal: Journal of translational medicine
Published: July 01, 2025
Dysregulated mitochondrial dynamics in cancer: Unlocking new strategies to combat drug resistance.
Journal: Biochimica et biophysica acta. Reviews on cancer
Published: June 16, 2025
DRP1-mediated mitochondrial fragmentation is a druggable vulnerability in multiple myeloma.
Journal: Blood
Published: June 11, 2025
Mitochondrial fission factor drives an actionable metabolic vulnerability in multiple myeloma.
Journal: Haematologica
Published: February 14, 2025
Hit Identification and Functional Validation of Novel Dual Inhibitors of HDAC8 and Tubulin Identified by Combining Docking and Molecular Dynamics Simulations.
Journal: Antioxidants (Basel, Switzerland)
Published: October 25, 2024
Targeting of mitochondrial fission through natural flavanones elicits anti-myeloma activity.
Journal: Journal of translational medicine
Published: January 25, 2024
Lipid metabolic vulnerabilities of multiple myeloma.
Journal: Clinical and experimental medicine
Published: July 13, 2023
Urinary Marinobufagenin in Patients with Non-Advanced Chronic Kidney Disease: A Cross-Sectional Study.
Journal: Medicina (Kaunas, Lithuania)
Published: July 12, 2023
Showing 1-11 of 11
Last Updated: 09/26/2026